Business · 06/12/2012
FDA Releases Guidance on Limiting Phthalate Use in Regulated Products
The FDA has made available a guidance document advising the pharmaceutical industry to avoid using certain phthalates, including DBP and DEHP, as excipients in CDER-regulated products to minimize potential human health risks.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →